Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
E S Mining in position!
https://www.eurosunmining.com/
t's HAPPENING! Gold & Silver to Blow Through the Roof -
with precious metals stock investor Peter Schiff
$SGMO +97% #DDAmanda Video Analysis - #1 Stock Scanner/Screener
Excellent entry point/refill - goldprice start moving up again - and so do the stock as well.
https://www.barchart.com/stocks/quotes/BBBXF/overview OTC
https://www.barchart.com/stocks/quotes/BBB.VN/overview TSX
Given goldprice climbing, silver resource awareness, high grade results from last update... things are moving!
https://brixtonmetals.com/
Maybe I´m wrong - still, I believe in a similar meltup as in 2016 this year/early 2025
$MIRA +626% #DDAmanda Video Analysis - #1 Stock Scanner/Screener
$AREB American Rebel Light Recaps Recent Beer Launch Success
https://finance.yahoo.com/news/american-rebel-light-recaps-successful-132900520.html
Nashville, TN, July 11, 2024 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) ("American Rebel" or the "Company"), a designer, manufacturer, and marketer of American Rebel Beer (www.americanrebelbeer.com) and branded safes, personal security and self-defense products and apparel, is proud to recap the successful launch of American Rebel Light Lager (“Rebel Light”) at the Country Stampede Music Festival (www.countrystampede.com) in Bonner Springs, Kansas June 27 – 29. Rebel Light is a premium domestic light lager, not a craft beer, and is initially being launched regionally and later slated for nationwide distribution. This was the first time Rebel Light was available for purchase in the state of Kansas, exclusively distributed in Kansas by Standard Beverage Corporation (www.standardbeverage.com), a leading beverage distributor in Kansas for 75 years and the “largest single alcohol distributor” in the state.
“Being featured at Country Stampede was a great way to launch America’s Patriotic, God-Fearing, Constitution-Loving, National Anthem-Singing, Stand Your Ground Beer in Kansas,” said Andy Ross, Chief Executive Officer of American Rebel. “I met most of the Standard Beverage sales team who were able to attend one of the three days of music, which I think has helped us hit the ground running in Kansas, putting us in over 100 retail locations in just a few weeks. The great exposure to the large Country Stampede crowds combined with the efforts of the Standard Beverage sales team has put us on the map in Kansas.”
American Rebel Beer was a sponsor of the “Party Pit,” the standing-room area in front of the stage. Country Stampede attendees at the Azura Amphitheater, with a capacity of 18,000 music fans, saw ads for American Rebel Light Beer on the giant jumbotrons on either side of the stage during the breaks between music acts and the American Rebel Light logo was printed on 2,500+ “Party Pit” wrist bands and featured along the front of the stage. Rebel Light was well-stocked backstage and in the VIP Lounge and many of the music acts enjoyed Rebel Light, including LOCASH, who brought Rebel Light out on stage with them and went on to post about Rebel Light on their social media accounts.
Brian Skurdal, Director of National Sponsorships for Forward Sports Marketing, said, “We were thrilled to play a small part in the launching of American Rebel Beer in the state of Kansas. The Country Stampede is one of the biggest and most historic country music festivals in the country; and American Rebel Beer will be a welcome addition for years to come.”
Chris Janson was Thursday’s featured artist, Riley Green, Friday’s featured artist had his set delayed 90 minutes due to a passing thunderstorm, and Jon Pardi was Saturday’s featured artist. Other artists scheduled to appear included Billy Currington, LOCASH, Randy Houser, Drew Green, Dillon Carmichael, Jackson Dean, Jerrod Niemann, Redferrin, Neon Union, Casi Joy, Tanner Adell and DJ Hish.
American Rebel and Standard Beverage Corporation both have deep roots in the Kansas City suburb of Lenexa, Kansas, where Standard Beverage has a new 83,000-square-foot facility and American Rebel has its safe showroom. Standard Beverage was started by Sam Rudd in the Wichita area in 1949, just a year after Kansas ended its prohibition laws, and received one of the first alcohol wholesaler licenses in the state. Standard Beverage is still run by the Rudd family today. American Rebel CEO Andy Ross’s father, Bud Ross, founded two legendary Kansas publicly-traded companies, Kustom Electronics and Birdview Satellite.
About Country Stampede
The Country Stampede, owned by Kustom Entertainment, a subsidiary of Digital Ally, Inc., is an annual 3-day outdoor music and camping festival that takes place in Bonner Springs, Kansas at Azura Amphitheater. The well-respected Country Stampede is nationally known as one of the largest music festivals in the Midwest. The biggest names in country music have performed at Country Stampede such as Kenny Chesney, Miranda Lambert, Reba McEntire, Taylor Swift, Chris Stapleton, Jason Aldean, Florida Georgia Line, Luke Bryan and so many more. For more information go to www.countrystampede.com.
About Standard Beverage Corporation
Standard Beverage Corporation is a leading distributor of fine wines, spirits and beer, and is the only large distributor that is Kansas owned. With offices in Lawrence, Lenexa and Wichita, Standard Beverage employs approximately 450+ dedicated people and provides the most diverse portfolio of the industry’s best and most well-known brands. For more information on Standard Beverage go to www.standardbeverage.com.
About American Rebel Holdings, Inc.
American Rebel Holdings, Inc. (NASDAQ: AREB) has operated primarily as a designer, manufacturer and marketer of branded safes and personal security and self-defense products and has recently transitioned into the beverage industry through the introduction of American Rebel Beer. The Company also designs and produces branded apparel and accessories. To learn more, visit www.americanrebel.com and www.americanrebelbeer.com. For investor information, visit www.americanrebel.com/investor-relations.
$KNOS FDA Greenlights Second Model in Kronos Advanced Technologies Inc.'s Revolutionary Air Purifiers Line
https://www.globenewswire.com/en/news-release/2024/07/10/2910961/0/en/FDA-Greenlights-Second-Model-in-Kronos-Advanced-Technologies-Inc-s-Revolutionary-Air-Purifiers-Line.html
$IFUS new tweet just out 1 hour ago
$IFUS #cattle #dairy #drought #beef #research #co2
— IMPACT FUSION INTERNATIONAL, INC. (@ImpactfusionI) July 12, 2024
Letter to the Shareholders 7-12-2024
Research-Validation-Commercialization https://t.co/Gopa2QzYhB
Back to Work!
$IFUS Huge New Update~~Watch Here⬇️
🔥$AAGC 🔥 Mega Thread! 💪
@HStarcuts 🔥🔥🔥 $AAGC 🔥🔥🔥🧵 Folks let’s take a look at where we are here:
— Nickeli (@nickeli54) July 9, 2024
✅ MC= $1M
✅ SS = 1.7B OS
✅ No Dilution
✅ No RS Stated many times
✅ Share buybacks monthly
✅ New Locations opening
✅ Audit underway
✅ Qtr over Qtr growth 🔥
✅Annual showed massive growth YOY pic.twitter.com/Bdy0upLSV5
🔥 $AAGC 🔥
💥 $AAGC 💥 Only takes one stock folks to change your life! 8’s hitting 🔥 patience usually plays well if it’s a 💎 Just have to peel back the onion to see what’s inside and this play is as clean as it gets! Take a peek at this annual and note share buy backs 👀 💎🔥💪 pic.twitter.com/kThR84MOuA
— Nickeli (@nickeli54) July 8, 2024
$CATV NEWS: Category V Biotech, Inc. Announces Exclusive Licensing of Genetic Networks' Intellectual Property for Cannabis Applications
FLORIDA, July 2, 2024 – Category V Biotech, Inc. (OTC: CATV), formerly known as 4Cable TV International, Inc., is pleased to announce significant progress in our relationship with Genetic Networks, LLC (https://geneticnetworks.com/).
While continuing to analyze the acquisition, Category V Biotech and Genetic Networks have agreed to allow CATV to become the exclusive licensee of all Genetic Networks’ intellectual property and technology worldwide for cannabis applications. This agreement allows Genetic Networks time to address internal matters found during due diligence, while Category V Biotech begins its journey into the discovery of medicines using cannabis. This licensing agreement will facilitate close collaboration with Genetic Networks on cannabis research and development, positioning Category V Biotech as a leader in developing cannabis medicines.
Our goal is to screen cannabis and cannabis-derived products to determine their medicinal benefits by utilizing Genetic Networks' extensive disease database accumulated over the past decade while working for pharmaceutical companies and government. Discovering the use of cannabis for specific diseases is key to developing medicines that can be registered with regulatory bodies worldwide and distributed for medical use or treatment.
The exclusive licensing of Genetic Networks’ technologies, including their proprietary platform GeneScape™, will facilitate the rapid and unbiased discovery of optimal drug compounds from cannabis through whole-genome analysis. This exclusive license allows Category V Biotech to expand into the biotech sector of the cannabis industry, leveraging Genetic Networks' expertise in accelerating compound discovery and development for pre-clinical and clinical testing.
"We are excited to welcome Genetic Networks into the Category V Biotech family," stated Michael Feldenkrais, CEO of Category V Biotech. "Their state-of-the-art platform and extensive knowledge will be instrumental as we strive to unlock the full potential of cannabis-based therapeutics. Together, we anticipate bringing novel treatments to patients faster than ever before, as regulated FDA products under the new regulatory environment of the United States." Dr. Gennaro D’Urso, co-founder of Genetic Networks, echoed this enthusiasm, stating, "Category V Biotech shares our dedication to leveraging genetics to revolutionize drug development. By joining forces, we envisage broadening the reach and impact of our platform, ultimately delivering superior medicines to patients in need."
Upon resolving internal matters identified during due diligence, Category V Biotech will complete the acquisition of Genetic Networks. Following the transaction, Genetic Networks will operate as a wholly owned subsidiary of Category V Biotech, retaining its existing management team and facilities. Category V Biotech plans to leverage Genetic Networks' capabilities across its global cannabis operations, including cultivation, biotech research, and retail. This transaction culminates years of discussions, awaiting the right moment for research and development in the United States to create pharmaceutical-grade products using cannabis.
The recent changes in the rescheduling of cannabis from Controlled Substance I to Controlled Substance III, reflecting a change in U.S. policies, has paved the way for Category V Biotech and Genetic Networks to capitalize on emerging opportunities in the cannabis industry, driving innovation and advancing therapeutic solutions for patients. Category V Biotech remains actively engaged in pursuing additional acquisitions in the cannabis industry as part of its growth strategy, with further transactions expected to be announced in the coming months.
About Genetic Networks, LLC
Established in 2015, Genetic Networks, LLC has been at the forefront of serving three of the top ten bio-pharmaceutical companies with its GeneScape™ technology. GeneScape™ expedites drug asset development through applied molecular biology, offering a multidimensional map of diseases and drugs that integrates genome-wide functional assays of drug activity (H-Tech) and human genes and gene variants (Y-Tech) using proprietary analytics. Genetic Networks' GeneScape™ platform accelerates the discovery and development of optimal candidate compounds for pre-clinical and clinical testing, identifying the optimal intersection between targets and compounds in specific disease spaces through whole-genome genetic perturbation and analysis. About Category V Biotech, Inc. Category V Biotech, Inc. (OTC: CATV) aims to establish and operate a fully integrated global cannabis company, encompassing biotech research, cultivation, manufacturing, and retail. Through strategic acquisitions and organic growth, the company strives to emerge as the world's leading provider of pharmaceutical cannabis-based products and therapies.
BIOL.....SEAT......MULN......CASI....https://stockcharts.com/h-sc/ui?s=CASI&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=MULN&p=W&b=5&g=0&id=p84354014936
https://stochttps://stockcharts.com/h-sc/ui?s=BIOL&p=W&b=5&g=0&id=p84354014936kcharts.com/h-sc/ui?s=SEAT&p=W&b=5&g=0&id=p84354014936
$EWRC Press release next week will encompass current and future projects. It will also include our 1st person POV game schedule with a detailed roadmap with one of the gaming world’s premiere platforms.
$EWRC’s press release next week will encompass current and future projects. It will also include our 1st person POV game schedule with a detailed roadmap with one of the gaming world’s premiere platforms.
— eWorld Companies, Inc (@eworld_company) June 28, 2024
$AVRW: How Seratopical Revolution by Nicole Kidman Is Changing The Game
Learn how Nicole Kidman and Nancy Duitch, founder and CEO of SeraLabs and Chief Strategic Officer of CURE Pharmaceutical have joined forces to launch SeraLabs' Seratopical Revolution, a plant-based, alcohol-free, anti-aging beauty line.
$AVRW Seratopical skin care products are keeping the famous Nicole Kidman looking her best.
When it comes to anti-aging skincare, Kidman's loyalty lies with Seralabs. Kidman, who has been working with the brand since 2020, told InStyle that she “loves using Seratopical because it makes my skin smooth and hydrated.” In honor of the brand ambassador’s birthday, Seralabs is offering 30 percent off sitewide all week with the code NK30.
Source:
https://www.instyle.com/nicole-kidman-birthday-favorite-beauty-products-8666305?utm_source=twitter&utm_medium=social&utm_campaign=shareurlbuttons
$AVRW: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results
New Initiatives Showing Encouraging Results
SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.
Key financial highlights for the fourth quarter included the following:
Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.
Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.
Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.
Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.
Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.
"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.
Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.
Operational Highlights
Other operational highlights during the fourth quarter of 2023 included:
Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/
About Avenir Wellness Solutions, Inc.
Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: http://www.avenirwellness.com.
About The Sera Labs, Inc.
Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: http://www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.
CONTACTS:
Investor Relations
Hanover International Inc.
T: (760) 564-7400
E: investor@avenirwellness.com
ESM Confirms Validity of Mining Licence and Option to Extend
https://www.globenewswire.com/news-release/2024/06/21/2902461/0/en/Euro-Sun-Mining-Confirms-Validity-of-Mining-Licence-and-Option-to-Extend.html
$CYCA: CyttaCARES - Revolutionizing Safety and Security in Educational Institutions
Cayman Islands , Dollinger started NewCo (a shell cooperation) in exchange for 6.0 million common shares of NewCo.
PlantX has agreed to exchange a collection of PlantX assets including wholly owned subsidiaries Vegaste Technologies US Corp., Little West LLC, Plant Based Deli LLC, and PlantX Living Inc., and the Company's 53% interest in Portfolio Coffee, Inc. and 51% interest Eh Coffee Corp.
With cross-owning ( PlantX owning 60% of NewCo ) one uses a way to exchange assets (value) between the two companies, in order to reduce insight to the actual transactions controlled by Dollinger and the PlantX company.
A common way to be able to avoid paying taxes on the assets registred in the Cayman Islands - see full article on Yahoo; https://finance.yahoo.com/news/plantx-enters-...00531.html
I`m reducing my shares in the company, will sell all asap as the company are of interest to the regulatory authorities - the same/similar scandal appears to be investigated, as the Dollinger - Namaste insider crime 2019.
Do your own research always.
$RDAR Trip-Zero Bottom Play! These 000 Bottom Plays can be very profitable sitting on the bottom so I am going to stick with them! Updates on the way per company!💫
$RDAR EPIC NEWS COMING SOON ABOUT A BLOCKBUSTER PARTNERSHIP 🏈🏈
— RAADR.com (@raadr_) June 5, 2024
A Multi Year Mining Opportunity!
https://brixtonmetals.com/
$DBMM>OTC INVESTMENT for 10,000% to 100,000%+ GAINS.
Growth towards NASDAQ has started as per below recent PRs, updates and tweets.
Many 10,000%+ runs coming. Just like last 2 10,000% and a 40,000% run.
Just getting started for next one.
With below, $DBMM setting up for NASDAQ = $$,$$$,$$$$
Digital Clarity Announces Strategic Alliance with Leading Transformation Consultancy 1ovmany.
Press Release - April 11, 2024.
https://www.accesswire.com/852296/digital-clarity-announces-strategic-alliance-with-leading-transformation-consultancy-1ovmany
"Company is pleased to announce the acquisition of a major software client headquartered in Austin Texas."
Shareholders Update - February 02, 2024.
https://www.dbmmgroup.com/shareholder-update-february-02-2024/
$DBMM MARCH 12, 2024 SHAREHOLDER UPDATE
https://www.dbmmgroup.com/shareholder-update-march-12-2024/
✅Why chose DBMM?
— DBMM Group Inc. (@dbmm_group) August 3, 2023
Positioned to disrupt multitrillion-dollar global market
Ground-floor investment opportunity
Comparisons to GameStop and AMC
▶️ https://t.co/3gFUr4fIVi#DBMM #OTC pic.twitter.com/fqIdWQMtjy
DBMM is positioned in the multitrillion-dollar global marketing consultancy market
— DBMM Group Inc. (@dbmm_group) October 24, 2023
DBMM’s Digital Clarity has a:
•Extensive black book
•Robust client base
•Current territories: Europe and U.S
•Future territories: U.A.E. and Asia pic.twitter.com/5gqpFWzbUV
$IVDN News on sales surge for superior, energy saving house wrap: Innovative Designs Sales Update
PITTSBURGH, PA- (NewMediaWire) - May 30, 2024 - Innovative Designs, Inc. (OTCQB: IVDN) continues its upward sales trend into the end of May 2024. Year-to-date sales have already surpassed FYE2023 by over 33% with 5 months remaining in FYE2024. The growth is attributed to a substantial increase in the number of new retailers that are now carrying the company's Insultex House Wrap®. As new energy codes are implemented across the United States, homebuilders/contractors are using Insultex House Wrap® as a convenient R-Value continuous insulation to a wall system.
Our notable growth in sales can be attributed to Built Link Solutions (Formerly Compound Construction) based in Grand Rapids, MI. Built Link Solutions is working to become the primary source for industry professionals, innovators, and stakeholders to discover, evaluate, and adopt the latest advancements in building materials, tools and technologies. Having curated a comprehensive national distribution network, they bring pioneering solutions like Insultex House Wrap® to market, propelling the evolution of the construction industry towards a future where innovation thrives, and buildings meet the needs of tomorrow. Since coming onboard, Built Link Solutions has:
Established a comprehensive national distribution network to service customers where they are when they need it.
Grown national awareness of product benefits and specifications through their dedicated sales agents and attendance at building industry trade shows across the country.
Conducted in-person sales training and online seminars to educate sales associates on Insultex House Wrap®.
Streamlined the sales process to deliver consistent and superior level service to customers of all sizes and needs.
Implemented volume pricing models and incentive discounts to meet the needs for scale and demand.
As building codes and exterior R-Value requirements are quickly evolving across the country, Built Link Solutions has proven highly proactive in contacting prospective accounts, notifying them of the cost-effective solution that our Insultex House Wrap® provides.
Randy Kimbler, Director of Business Development for Built Link Solutions, commented, "Insultex House Wrap® is gaining traction in the market as it provides a timely and effective solution. Its cost-effectiveness, innovation, and ability to address today's building challenges are driving positive feedback nationwide."
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest, and warmest insulator in the market today. For more information, please visit:
http://www.idigear.comorhttp://www.insultexhousewrap.com.
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available athttp://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph Riccelli, CEO
412-799-0350
joer@idigear.com
http://www.insultexhousewrap.com
Built Link Solutions
Randy Kimbler, Dir. Business Development
616-443-3200
RandyK@Builtlinksolutions.com
News Source: Innovative Designs Inc.
TROILUS GOLD 500% Upside now to target price;
https://www.barchart.com/stocks/quotes/TLG.TO...st-ratings
(see today`s news)
$GRLF: Green Leaf Innovations, Inc. Sets Sail for History
Join Cubanacan Heritage at Battleship New Jersey Museum's Annual 'Cigars on the River' Event
PEMBROKE PINES, FL / ACCESSWIRE / May 15, 2024 / Green Leaf Innovations, Inc., (OTC PINK:GRLF), an importer and wholesale distributor of premium hand-rolled cigars, is proud to announce its participation in the highly anticipated 'Cigars on the River' event at the iconic Battleship New Jersey Museum and Memorial.
Overlooking the majestic Delaware River and the breathtaking Philadelphia skyline, this annual soirée promises an unforgettable evening of indulgence and philanthropy. Guests will savor the finest cigars, exquisite cuisine, and handcrafted cocktails amidst the historic setting of the Battleship New Jersey.
Cubanacan Heritage, a cornerstone of Green Leaf Innovations, Inc.'s esteemed portfolio, will take center stage at this prestigious event, showcasing the rich heritage and unrivaled craftsmanship behind each meticulously hand-rolled cigar.
About Battleship New Jersey Museum and Memorial: The Battleship New Jersey Museum and Memorial stands as a testament to our nation's military prowess and enduring legacy. From its storied past in World War II to its pivotal role in modern naval history, the battleship offers a captivating glimpse into the triumphs and sacrifices of our armed forces. Immerse yourself in a journey through time and honor the heroes who have served our country with courage and valor.
Don't miss this exclusive opportunity to join Green Leaf Innovations, Inc. and Cubanacan Heritage aboard the Battleship New Jersey for an evening of camaraderie, celebration, and support for a noble cause.
About Green Leaf Innovations, Inc.
Green Leaf Innovations, Inc., a Florida corporation, is an emerging growth company engaged in the Marketing and Distribution of handmade premium cigars. The company strategically imports and exclusively distributes some of the best known premium cigar brands in the Market created by the Mederos family a Third generation Cigar maker with Robert Mederos at the helm who has owned and operated handmade cigar operation in Nicaragua and the US for over 20 years with a rich family history in the craft dating back to the 1800s Cuba, brands such as CUBANACAN, MEDEROS and TABACALERA SERRANO. In addition to it the company also distributes packaged whole leaf Tobacco to cigar lounges, smoke shops, C-stores and vape shops across the United States and soon International Markets.
Additional information can be found on our websites http://www.greenleafinnovation.com or follow us on Twitter @otcgrlf.
For more information, press only:
PR Contact Name: Ryan Medico
Phone number: (800) 303-6268
Email: info@greenleafinnovation.com
Safe Harbor Statement:
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. The Company may also make written or oral forward-looking statements in its filings with the U.S. Securities and Exchange Commission, in press releases and other written materials, and in oral statements made by its officers, directors or employees to third parties. There can be no assurance that such statements will prove to be accurate. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Reports on Form 10-K and its other filings with the Securities and Exchange Commission. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control. The Company does not undertake any obligation to update publicly or to revise any statements in this release, whether as a result of new information, future events, or otherwise.
SOURCE: Green Leaf Innovations, Inc.
Romania Government Align Mining Legislation to EU 's Critical Raw Materials Act
https://crweworld.com/article/news-provided-by-globenewswire/3364861/romania-government-announces-strategy-to-align-mining-legislation-to-the-eu-s-critical-raw-materials-act
https://www.eurosunmining.com/
BULLISH
New Bio Tech Company: $CATV at Ground Floor
$CATV announced today the execution of a Letter of Intent (LOI) to acquire Genetic Networks, LLC (https://geneticnetworks.com/), a leader in applied molecular biology and drug development.
Z
"BREAKOUTS_RUNNERS_AND_HOT_PENNIES" Check out the new Ihub Board Below... Come by and post often!
https://investorshub.advfn.com/BREAKOUTS-RUNNERS-AND-HOT-PENNIES-7145
Come Post Your Plays! News!
Latest video interview Sean Dollinger, the founder of the company PlantX Life
Sean Dollinger, PlantX - November 30, 2023
https://investorshub.advfn.com/PlantX-Life-Inc-VEGA-38643
PlantX Investors now on fb as well
$AVRW Feature Article: Seratoptical Revolutions Skin Care Products placed in Famed Summer Beauty Box FabFitFun with over 2 Million Subscribers Recommendations from High Profile Celebrities, Influencers & Top Medical: AVRW
Click here:
http://markets.financialcontent.com/bostonherald/article/getnews-2024-5-14-seratoptical-revolutions-skin-care-products-placed-in-famed-summer-beauty-box-fabfitfun-with-over-2-million-subscribers-recommendations-from-high-profile-celebrities-influencers-and-top-medical-avrw/
$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024
RADNOR, Pa., May 8, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will participate in the EF Hutton Annual Global Conference, which will take place on May 15, 2024, at The Plaza Hotel in New York City.
Prof. Jonathan Javitt, MD, MPH, the Company's Chairman and Chief Scientist, and Matthew Duffy, the Company's Chief Business Officer, will hold one-on-one meetings with investors throughout the day. Interested parties can register to attend here.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
https://c212.net/c/img/favicon.png?sn=CL08030&sd=2024-05-08 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-to-participate-in-the-ef-hutton-annual-global-conference-on-may-15-2024-302139427.html
SOURCE NRx Pharmaceuticals, Inc.
PLANTX Life 1 year forecast $3.5310, a +17082.70%
increase from the current price of $0.0206.
https://stockscan.io/stocks/PLTXF/forecast
SNAX.......................MULN..............................https://stockcharts.com/h-sc/ui?s=SNAX&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=3&dy=0&id=p11960084343
$IFUS has gone way beyond the concept stage. You may have missed the recent news on CBS, and multiple non pump style OTC Markets shareholder letter updates.
One PR was the news that Roberts son Trey Schmidt (6th generation Texas Cattle rancher) at the family ranch that ran the first SGP+(tm) IFUS Game changer cattle feed trials, and then the father and son and ranch hands were so impressed they funded the next stage of IFUS with trapped for 2 years PP shares (the company has zero convertible debt), The son Trey Schmidt, who is a Millionaire, with 20 years of International Business experience is now the VP pf International Businees at IFUS, in charge of the JV start up in India, that will build and run the plant using India Bagasse from 11 sugar mills the JV Partner own, to feed their 500,000 dairy cows.
Which is about 0.1% of the India Sugar Mills and Dairy cows...
India can add $20/share to the IFUS share price alone.
Brazil will be next.
We are way beyond the concept stage.
Recent news was also out that they invested in new machinery that cut the shipping costs of IFUS 16X, a 16X factor reduction in the shipping costs, so that IFUS Cattle feed is cost effective to ship nation wide and by Barge and in Massive dry Bulk ships, over seas...
Also the Human supplement line is back in stock now, and orders are being filed for IFUS Intact Digest
Ask me why I think this stock will hit a $100/share and be paying dividends on Nasdaq in the future...
Nice!!!........... $IFUS has a great concept..........
Z
$IFUS Massive Updates:
https://www.otcmarkets.com/otcapi/company/dns/news/document/73381/content
https://www.otcmarkets.com/stock/IFUS/news/IFUS-SGP-Game-Changer?v&id=7071
4 weeks ago:
final version of the **CBS news covering IFUS** tonight is out. It was recorded. The Text version has a link the front page of the IFUS website that features the SGP+(tm) game changer cattle feed. The story is about IFUS SGP+(tm) cattle feed donation to the North Texas cattle owners to help save what is left of their cattle, and the fact that this new super low cost game changer cattle feed is a huge solution to climate change driven disasters like North Texas suffered last week, that destroyed 1.1 Million acres of grass and cattle industry assets.
https://www.wafb.com/2024/03/07/new-innovative-cattle-feed-being-donated-north-texas/
Professional Emmy award winner, IFUS shareholder Video made for IFUS for free. Gifted to IFUS by a friend of mine:
I agree..........also, guys should look at $IDGR......Massive assets moving in, and revenues to boot.....next Q will reflect that and it's due shortly......
Z
Indeed, and that Clock is running out fast to load $IFUS $SAPX and $BIXT
Financials should be out mid week on IFUS, and then IMO mega news, so Thoughts and prayers for any one that is short IFUS or holding an empty bag, LOL.
AI and PLANTX, analysing the different aspects of a companies value.
Text below is a sum up by AI; calculations of PlantX reported filings 2023.
The previous year, PlantX focused on profitable growth,
resulting in strong financial performance.
1. Develop high-growth businesses: PlantX's strategic approach is to
nurture its high-growth businesses and make necessary adjustments
for those that don't meet stringent growth and margin thresholds.
2. The company operates with limited overhead costs and inventory,
maximizing margins and ultimately net income, gaining strength.
3. Improve efficiency and customer experience: PlantX consolidated
XMarket Squamish and Cloudburst Coffee shop at Locavore Bar
and Grill to improve efficiency and customer experience.
4. Create Chicago's Groundbreaking Vegan Foodhall: The company is in
the process of creating Chicago's groundbreaking Vegan Foodhall,
XMarket Uptown and this process continues during this year.
Let`s see how long time until we are profitable!
https://vegainvestors.com/
$RDAR .001 - .00673 1-Yr Forecast by WalletInvestor - News next week and #ArtificialInteligence coming to the #app here. Things are looking up from the bottom here!
https://twitter.com/raadr_
💲🛫$EARI 000 weed plays can be as fruitful as the recent 000 crypto theme was recently.
$AGBA AGBA Group: Triller Merger Creates Significant Speculative Upside If TikTok Gets Banned In The U.S.
https://seekingalpha.com/article/4685179-agba-group-triller-merger-creates-significant-speculative-upside-if-tiktok-gets-banned-in-the-us
PLBY.........................MULN............................https://stockcharts.com/h-sc/ui?s=PLBY&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=3&dy=0&id=p11960084343
Fair enough.......just like to post to my friends every once in a while........lol
Z
I am not waiting for software buy signals, LOL, I have BIXT news / analyst dots connected.
GM sir. Enjoy!!!
$BIXT News analyst paper
https://www.nasdaq.com/press-release/6-stocks-positioned-to-soar-as-investors-focus-on-mash-2024-04-22
For those in a rush, slow readers, skip down the bottom for $BIXT connect the dots, connection.
Investing requires leading with an edge and some forethought. This article highlights pure-play drug developers in MASH likely to be the focus of investors looking for the next big thing in biotech.
Looking Beyond GLP-1 Inhibitors Toward the MASH Epidemic
Drug makers like Eli Lilly (NYSE: LLY) with their drug Mounjaro (tirzepatide) have already repurposed their drug once and are looking beyond diabetes and obesity, with their eyes set on and an even more lucrative market of metabolic dysfunction-associated steatohepatitis (MASH). LLY has promising interim clinical data showing 74% of overweight adults who took the higher dose of tirzepatide cleared MASH versus 12.6% in placebo. The first approval of a MASH drug on March 15, 2024 by Madrigal Pharmaceuticals (NASDAQ: MDGL) has ignited the sector with investors looking for the next big pure play.
Multiple MASH Targets
Metabolic dysfunction-associated steatohepatitis (MASH) is a complicated disease on the regulatory front. Approval criteria are a resolution of MASH symptoms via biopsy without a worsening of fibrosis. The disease formerly known as nonalcoholic steatohepatitis (NASH) is caused by a buildup of fat in the liver that leads to complications which include fibrosis (scarring of the liver), cirrhosis (severe scarring of the liver), and liver cancer. Once MASH progresses this far, liver transplantation is currently the only viable option. After MDGL’s approval of Rezdiffera®, investors have been flocking to other MASH names looking for a follow-on drug that either works in combination with Rezdiffera or one that is superior in safety and efficacy.
MASH Drug Targets
MASH has several druggable targets. The GLP-1 target is the mainstream approach because it also treats type 2 diabetes. Next in terms of a drug target is the fibroblast growth factor 21 (FGF21) which has a number of players in late-stage development. Galectin-3 is another target for MASH drugs as research has shown it is implicated in fibrotic and inflammatory feedback loops. There are also promising drugs that target the thyroid hormone receptor beta (THRß). Breaking from the mainstream approaches is the A3 adenosine receptor (A3AR) which is highly expressed in inflammatory and cancer cells whereas low expression is found in normal body cells.
FGF21 Agonists
89Bio Inc. (NASDAQ: ETNB) is developing a lead molecule called pegozafermin which is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). It is similar in mechanism of action to Bristol Myers Squibb’s (NYSE: BMY) drug pegbelfermin which was discontinued despite positive results which showed more than half the patients having NASH resolution at 16 weeks. FGF21 analogues are taken via subcutaneous injection. The targeting of the FGF21 pathway helps regulate metabolism and cellular process, especially in the liver fat tissue. Balancing out this metabolic pathway helps reduce liver fat, which can result in reduction in liver fibrosis (scarring) over time. The company has strong fibrosis data with favorable tolerability and dosing convenience. The long term data suggests there is a cumulative impact on patients taking background GLP-1 therapy. ETNB’s phase 3 program in MASH could achieve accelerated approval using histology in non-cirrhotic (F2-F3) and cirrhotic (F4) patients although the FDA has acknowledged greater importance in clinical outcomes and not histology. They have clinical trials in both fibrosis and cirrhosis and expect to initiate their cirrhosis trial in Q2 2024. The company has almost $600 million in cash with a market cap of $875 million. The slight premium over cash, solid and consistent trial results, along with short and long-term catalysts make this an attractive setup for investors. This is the first on the top 6 list.
Akero Therapeutics (NASDAQ: AKRO) is also targeting MASH and MASH cirrhosis with an FGF21 agonist. Their drug is called efruxifermin and is commonly referred to as EFX. In their phase 2b MASH trial they showed a 65% reduction in liver fat content vs 11% in placebo which places them close to the front of the pack because it was done in only 12 weeks. Unfortunately, their phase 2b trial in MASH missed the endpoint for improvement in liver fibrosis at the 12-week time frame but showed 60% had MASH resolution after 36 weeks versus 26% in placebo. The company lost a lot of value on that readout but the statistics show a cleanly designed trial is likely to hit the regulatory endpoints. Guidance from an end-of-trial FDA meeting is forthcoming, but the timing is still uncertain and weighing on the stock price. While there is a lot of potential in this name, the uncertain timing of the regulatory pathway makes this ideal for the patient investor looking more for a NASH cirrhosis play. The company is well funded with over $550 million in cash and a $1.5 billion market cap.
Galectin-3 Antagonists
Galectin Therapeutics (NASDAQ: GALT) has an adaptive design phase 2/3 study in NASH cirrhosis with an interim readout before year end 2024. Their intravenously administered galectin antagonist called belapectin showed complete prevention of esophageal varices in a phase 2 trial despite failing to meet their (now defunct) primary endpoints. Their pivotal trial used lessons learned from the phase 2 trial, utilizing a primary endpoint of prevention of esophageal varices. If the interim results confirm a complete or near complete prevention of varices like they did in their phase 2 trial, they would have a compelling argument for conditional approval, likely with another post-market confirmatory phase 3 trial. Almost 50% of patients that develop esophageal varices die within a year, and the varices are extremely costly to treat. So eliminating the significant and imminent threat of death is the compelling benefit.
The company is in solid financial shape with enough cash runway to complete their pivotal trial by 2025. They also have the backing of a billionaire investor who is also their Chairman of the Board. Additionally, their drug demonstrated promising results in cancer, psoriasis, and atopic dermatitis which could lead to a label expansion once they are approved. The market cap of the company is sitting around $225 million despite the near certainty of a positive interim trial readout within the next 8 months, which could translate into billions within that time frame.
The company is not alone in the space and has 2 other competitors with oral galectin-3 antagonists. Galecto Bioscience (NASDAQ: GLTO) announced they were scrapping their cancer drug, which had a 60% response rate after three months, to focus on NASH. GLTO had a failed trial in idiopathic pulmonary fibrosis because of their drug’s poor tolerability, which has forced them to seek strategic alternatives with a focus on liver disease. As a result, their development timelines for MASH are in flux. Galecto’s small molecule approach to inhibiting intracellular galectin-3 is the likely culprit for their drug’s poor tolerability and its more likely large molecules which target extracellular galectin-3 will succeed.
Bioxytran Inc. (OTCMKTS: BIXT) has the most technologically advanced oral galectin antagonist that completed phase 2 trials in standard risk COVID-19, but the company is underfunded and therefore moving forward cautiously. Both Bioxytran and Galectin Therapeutics are developing larger molecules compared with Galecto and both their drugs have been found to be safe as opposed to Galecto. Bioxytran’s additional benefit is that their drug doesn’t require intravenous administration. Their clinical trials in NASH or cancer are dependent upon them finding a partner or a couple million dollars to get a shot at a number of multibillion dollar opportunities. Management indicated that the quickest way to approval was a COVID-19 regulatory approval and then proceeding with the label expansion. While the company boasts impressive technology and experienced management, they don’t have the resources to prove their technology for all these indications yet. It's for these reasons that the stock should remain high on peoples watch lists—in case they get funding.
See the article for the rest of the story
#Stockstobuy #StocksInFocus #OTC
$MULN $KIRK $NIOS $NVDA
$KITL $CGRA $TGLO $BLLB $VDRM $BLEG $BLFR $BLLB
$CISO $CLNV $CNER $CSCO $DBMM $ELTP $ENZC $FDCT
$GNS $GOLD $GVSI $HHSE $HMBL $HPNN $HYMC $KATX
$KITL $KRTL $LWLG $MMTMF $MMY $MMM $MSFT $MULN
$NHMD $NWBO $RGBP $RNVA $SMME $SRNW $STAL $TGT
$TGTX $OPK $OPXS $TSLA $WMT $YCRM $ZHUD
$GBTC $TCEHY $LKNCY $NTDOY $RHHBY $LTCN $BEGI $YCRM $NWBO $GVSI
$HMBL $DZNY $BLEG $INBS $PRSO $JAGX $SNTI $JAN $ASTR
$RDRSF $RGBP $EPAZ $BIXT $IFUS $MSOS $CCHW $CCHWF $GRAM $GRAMF $VRNO $VRNOF $GDNSF $TRUL $TCNNF
$AYR $AYRWF $CURA $CUR $CBDLLF $TLRY $CGC $HEXO $PPCB $HEMP $XCPL $PHIL $MCOA $BANT $PVSP $GRLT $INND $BBRW $MMEX $TONR $ICNM $IDVV
$GBTC $TCEHY $LKNCY $DIDIY $SONG $MCLE $ETCG $GDLC $TOELY $NWBO $GVSI $BEGI
$TMGI $NLST $INBS $TCON $INVO $MRAI $IONM
$EVKRF $GME $GOLD $GVSI $IDVV $KATX
$LITOF $LQMT $LTHM $LTUM $LWLG $MMM $MMTMF $MMY $NBIO $NHMD
$NVDA $NWBO $PEIMF $RDHL $RIVN $RNVA $AABB $ABQQ $AMC $ATMH $AVXL $BBRW $BEGI $BLEG $BLFR $CBIA $CDSG $CLNV $CYTO $DBMM $DTCK
$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
New data demonstrates no impact of NRX-101 on gut or vaginal flora – considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infections
NRX-101 previously demonstrated potent activity against resistant urinary pathogens and has been shown to be fully excreted, unmetabolized, in the urine
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation in Complicated Urinary Tract Infection (cUTI) and Pyelonephritis
RADNOR, Pa., April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs such as ciprofloxacin. Antibiotics commonly used to treat complicated urinary tract infections (cUTI) are associated with pseudomembranous colitis caused by Clostridium difficile (C diff) and vaginal yeast infections, primarily owing to their impact on normal flora.
C. diff causes an intractable diarrhea in approximately 500,000 Americans each year and kills 1 in 11 Americans over age 65 who contract the infection. Costs of C. diff are estimated at $24,000 per patient and are significantly higher when C. diff occurs as part of a hospital admission. Whereas most antibiotics have substantial effect in the large bowel, the key component of NRX-101 (D-cycloserine) is entirely absorbed in the small intestine and excreted unmetabolized in the urine. If the nonclinical data reported today are replicated in patients, NRX-101 could represent the first antibiotic for cUTI and pyelonephritis that has essentially no risk of causing C. diff infection or vaginal yeast infection. There is an extensive literature surrounding the use of D-cycloserine to treat tuberculosis and cases of C. Diff are unknown.
D-cycloserine's effect as an antibiotic is based on its propensity to substitute for the amino acid alanine in the formation of the bacterial cell wall.
Dr. Michael Manyak, noted Professor of Urology and former Global Medical Director for Urology at Glaxo SmithKline stated "As a Urologist, I'm acutely aware of the importance of avoiding common side effects of current antibiotics. NRX-101's lack of impact on normal flora could potentially confer a distinct advantage for the product in for the treatment of cUTI and pyelonephritis. This profile could change the lives of the half million Americans each year who contract C. diff and save lives among the tens of thousands who die from antibiotic-induced C. diff infections. These potential advantages should make NRX-101 even more attractive to potential partners in this multi-billion-dollar market." Dr. Manyak serves as NRx's Medical Thought Leader for urology.
"While we have primarily focused on NRX-101 as a drug to treat CNS disease, these new and highly provocative findings suggest that NRX-101 could find a home as a first line treatment for cUTI and pyelonephritis, which afflicts more than 3 million Americans each year. Should the rodent model findings prove applicable to the people, the use of NRX-101 to treat cUTI without increasing the risk of C. diff infection could have multibillion dollar potential," said Stephen Willard, JD, Chief Executive Officer of NRx pharmaceuticals.
About D-Cycloserine in cUTI
The active antibiotic ingredient of NRX-101 is D-cycloserine (DCS) that was developed as an antibiotic in the 1950's and used worldwide for the treatment of tuberculosis. However, it fell out of favor with the development of trimethoprim/sulfa and various penicillins, cephalosporins, and tetracyclines, in part because of the CNS effects associated with DCS-induced blockade of the brain's NMDA receptor. In the course of its CNS research, NRx Pharmaceuticals has demonstrated that small doses of lurasidone counteract those CNS effects, potentially providing a new therapeutic life to DCS as an antibiotic. Over the ensuing decades, increased antibiotic resistance has rendered standard treatments for UTI ineffective in many cases and today 3 million Americans suffer from cUTI requiring increasingly toxic antibiotics, increasingly frequent intravenous therapy, and increased need for hospital admission. (Lodise TP, et. al. Open Forum Infectious Diseases https://doi.org/10.1093/ofid/ofac307)
Because DCS has the unique property of being highly concentrated, unmetabolized, in the urine with oral administration, the Company believes, and previous literature has suggested that DCS may effectively treat, and therefore help prevent, the need for intravenous and inpatient treatment of cUTI.
Moreover, because DCS is rapidly absorbed and excreted in the urine, NRX-101 has now been shown to have minimal tendency to disrupt the microbiome of the intestine and vagina and which can lead to secondary Clostridium difficile and/or yeast infections. C. diff associated colitis doubles hospital mortality and costs the American healthcare system up to $1.6 billion each year. (Drozd EM, et. al. Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection DOI: 10.1097/IPC.0000000000000299) Additionally, DCS has no known association pulmonary fibrosis, a rare, lethal condition that has been associated with macrolide (tetracycline family) antibiotics.
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations in Complicated Urinary Tract Infection and Pyelonephritis.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL90042&sd=2024-04-17 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-announces-new-data-on-nrx-101-demonstrating-no-damage-to-intestinal-and-vaginal-flora-in-validated-rodent-models-compared-to-standard-antibiotics-potential-implications-for-avoidance-of-c--302119157.html
SOURCE NRx Pharmaceuticals, Inc.
Followers
|
675
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
50238
|
Created
|
08/26/13
|
Type
|
Free
|
Moderator TenTimesPay | |||
Assistants Papa Bear BLULLISH yankee2 $Pistol Pete$ |
Posts Today
|
0
|
Posts (Total)
|
50238
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |